Equity Profile

BNTX

BioNTech SE

Health CareBiotechnology$25.1B

Aug4Tue

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

BioNTech SE is a biotechnology company focused on developing and manufacturing immunotherapies for cancer and infectious diseases. As a key player in the health care sector, it gained significant attention for its COVID-19 vaccine, which highlights its role in addressing global health challenges.

Key Metrics to Watch

EPS

Earnings per share will indicate the company's profitability and how well it is managing costs, especially in the wake of recent losses.

N/A

Revenue

Revenue figures will provide insight into the company's sales performance and market demand for its products.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

BNTX Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

63%

Avg EPS Surprise

+9.61%

Avg Stock Reaction

-4.09%

Last Quarter Recap

In the last quarter, BioNTech reported an EPS of -$2.28, which was better than the expected -$2.52, resulting in a positive surprise of 9.45%. However, the stock declined by 3.88% the following day, indicating market concerns despite the beat.

Management Promises & Guidance

Focus on advancing pipeline candidates.
Commitment to reducing operational costs.
Plans to expand partnerships for new therapies.

Expectations

Wall Street Expectations

Overall, investors are cautious ahead of the earnings report, given the company's recent history of losses and mixed performance. The lack of analyst estimates adds uncertainty to market expectations.

Bull Case

If BioNTech can demonstrate strong revenue growth and effective cost management, it could regain investor confidence and drive the stock higher.

Bear Case

Continued losses or disappointing revenue figures could lead to further declines in stock price, as investors may lose faith in the company's turnaround potential.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will be the specific revenue figures for the current quarter?

Revenue is critical for assessing the company's market traction and overall health, especially given recent losses.

How much is BioNTech planning to invest in R&D this quarter?

Investments in R&D will indicate the company's commitment to innovation and its future growth potential.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating BioNTech's potential for revenue growth due to its pipeline advancements and partnerships, which could lead to stronger-than-expected results.

Supporting Evidence

Recent R&D advancements suggest potential new revenue streams.

The options market implies a larger move than historical averages, indicating investor anticipation.

Insider selling may not reflect company performance but rather personal financial decisions.

Key Risk

If revenue exceeds $500 million, it could challenge the current cautious consensus.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate centers around whether BioNTech can effectively manage costs while driving revenue growth in a competitive biotech landscape.

Bull Confirmed If

A revenue figure exceeding $500 million would confirm strong market demand and operational efficiency.

Bear Confirmed If

Revenue below $300 million would signal ongoing challenges and could lead to further stock declines.

Pre-Earnings Positioning

Options Market

Implied Move

±10.69%

Historical Avg

±4.7%

Pricing rich

The options market is pricing in a significant potential move, suggesting that investors are anticipating volatility around the earnings announcement.

Options are pricing ±10.7% while BNTX has averaged ±4.7% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.5%

30d HV

37.4%

Calls (22K)P/C Ratio: 0.41Puts (26K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 5.5%, with a raw directional average of +2.9% (modestly positive historical bias).

Edge

Insider Activity

Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.

Bought

$0.00

0 sh

0 insiders

Sold

$5.5M

50,000 sh

1 insider

Net

$5.5M

Net selling

Most Active Insiders· 1 open-market trade

Chief Operating OfficerPoetting Sierk
$5.5M
Net selling

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If BioNTech beats expectations, history suggests a potential average one-day move of +2.89%, confirming a positive outlook.

In-Line / Cautious

An in-line report may lead to muted reactions, as management commentary could drive the stock's direction.

Miss

If the company misses expectations, history suggests an average one-day decline of -7.43%, reflecting investor disappointment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Details on revenue performance compared to previous quarters.
2Updates on R&D investments and pipeline progress.
3Management's outlook on future sales and market conditions.
4Any new partnerships or collaborations announced.
5Insights into cost management strategies moving forward.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug3

ONBMO

ON Semiconductor Corporation

PreviewView

Aug3

LBMO

Company Snapshot

Key Metrics to Watch

EPS

Earnings per share will indicate the company's profitability and how well it is managing costs, especially in the wake of recent losses.

N/A

Revenue

Revenue figures will provide insight into the company's sales performance and market demand for its products.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

BNTX Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

63%

Avg EPS Surprise

+9.61%

Avg Stock Reaction

-4.09%

Last Quarter Recap

Management Promises & Guidance

Focus on advancing pipeline candidates.
Commitment to reducing operational costs.
Plans to expand partnerships for new therapies.

Expectations

Wall Street Expectations

Bull Case

If BioNTech can demonstrate strong revenue growth and effective cost management, it could regain investor confidence and drive the stock higher.

Bear Case

Continued losses or disappointing revenue figures could lead to further declines in stock price, as investors may lose faith in the company's turnaround potential.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will be the specific revenue figures for the current quarter?

Revenue is critical for assessing the company's market traction and overall health, especially given recent losses.

How much is BioNTech planning to invest in R&D this quarter?

Investments in R&D will indicate the company's commitment to innovation and its future growth potential.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating BioNTech's potential for revenue growth due to its pipeline advancements and partnerships, which could lead to stronger-than-expected results.

Supporting Evidence

Recent R&D advancements suggest potential new revenue streams.

The options market implies a larger move than historical averages, indicating investor anticipation.

Insider selling may not reflect company performance but rather personal financial decisions.

Key Risk

If revenue exceeds $500 million, it could challenge the current cautious consensus.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate centers around whether BioNTech can effectively manage costs while driving revenue growth in a competitive biotech landscape.

Bull Confirmed If

A revenue figure exceeding $500 million would confirm strong market demand and operational efficiency.

Bear Confirmed If

Revenue below $300 million would signal ongoing challenges and could lead to further stock declines.

Pre-Earnings Positioning

Options Market

Implied Move

±10.69%

Historical Avg

±4.7%

Pricing rich

The options market is pricing in a significant potential move, suggesting that investors are anticipating volatility around the earnings announcement.

Options are pricing ±10.7% while BNTX has averaged ±4.7% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.5%

30d HV

37.4%

Calls (22K)P/C Ratio: 0.41Puts (26K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

Edge

Insider Activity

Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.

Bought

$0.00

0 sh

0 insiders

Sold

$5.5M

50,000 sh

1 insider

Net

$5.5M

Net selling

Most Active Insiders· 1 open-market trade

Chief Operating OfficerPoetting Sierk
$5.5M
Net selling

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If BioNTech beats expectations, history suggests a potential average one-day move of +2.89%, confirming a positive outlook.

In-Line / Cautious

An in-line report may lead to muted reactions, as management commentary could drive the stock's direction.

Miss

If the company misses expectations, history suggests an average one-day decline of -7.43%, reflecting investor disappointment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Details on revenue performance compared to previous quarters.
2Updates on R&D investments and pipeline progress.
3Management's outlook on future sales and market conditions.
4Any new partnerships or collaborations announced.
5Insights into cost management strategies moving forward.